Literature DB >> 23335603

Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era.

Enrico Cerrato1, Fabrizio D'Ascenzo, Giuseppe Biondi-Zoccai, Andrea Calcagno, Simone Frea, Walter Grosso Marra, Davide Castagno, Pierluigi Omedè, Giorgio Quadri, Filippo Sciuto, Davide Presutti, Giacomo Frati, Stefano Bonora, Claudio Moretti, Fiorenzo Gaita.   

Abstract

AIMS: Human immunodeficiency virus infection (HIV) has been associated with cardiac dysfunction that, if present, can negatively affect morbidity and mortality of HIV-infected patients. Unfortunately, many of the studies on this topic were performed before the highly active antiretroviral therapy (HAART) was established. Thus, we performed a comprehensive meta-analysis to critically appraise the incidence of cardiac dysfunction in HIV-infected pauci symptomatic patients. METHODS AND
RESULTS: Medline, Cochrane Library, and Biomed Central were systematically screened for studies reporting on systolic and/or diastolic dysfunctions in HIV pauci-symptomatic patients. Baseline treatment and cardiac imaging data were appraised and pooled with random effect methods computing summary. At pooled analysis, including a total of 2242 patients from 11 studies, an overall average incidence of traditional cardiovascular risk factors was observed, while a low rate of previous coronary artery disease was reported. Incidence of systolic and diastolic left ventricular dysfunction was 8.33% (95% CI: 2.20-14.25) and 43.38% (95% CI: 31.73-55.03), respectively. Diastolic dysfunction was graded as first [31.85% (95% CI: 24.85-43.73)], second [8.53% (95% CI: 2.12-14.93)], and third degree [3.02% (95% CI: 1.78-4.27)]. At multivariate analysis, a high sensitivity C-reactive protein level >5 mg/L, active tobacco smoking and previous history of myocardial infarction were predictors of left ventricular systolic dysfunction [odd ratio 1.70 (95% CI: 1.03-2.77); 1.57 (95% CI: 1.03-2.34); and 15.90 (95% CI: 1.94-329.00), respectively]. Hypertension (OR = 2.30; 95% CI: 1.20-4.50) and older age (OR = 2.50 per 10 years increase; 95% CI: 1.70-3.60) were predictors of left ventricular diastolic dysfunction (Figure  3).
CONCLUSIONS: Systolic and diastolic dysfunction represent a common finding in pauci symptomatic HIV-infected patients, regardless to HAART.

Entities:  

Keywords:  Antiretroviral therapy; Echocardiography; HAART; HIV; Heart failure

Mesh:

Year:  2013        PMID: 23335603     DOI: 10.1093/eurheartj/ehs471

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  45 in total

1.  Human Immunodeficiency Virus-Associated Myocardial Diastolic Dysfunction and Soluble ST2 Concentration in Tanzanian Adults: A Cross-Sectional Study.

Authors:  Justin R Kingery; Parag Goyal; Rahul Hosalli; Myung Hee Lee; Bernard Desderius; Fredrick Kalokola; Abel Makubi; Salama Fadhil; Saidi Kapiga; Dipan Karmali; Daniel Kaminstein; Richard Devereux; Margaret McNairy; Warren Johnson; Daniel Fitzgerald; Robert Peck
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

Review 2.  Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults.

Authors:  Robert C Kaplan; David B Hanna; Jorge R Kizer
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 3.  HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease.

Authors:  Revery P Barnes; John Charles A Lacson; Hossein Bahrami
Journal:  Curr Atheroscler Rep       Date:  2017-05       Impact factor: 5.113

Review 4.  Cardiovascular Complications of HIV in Endemic Countries.

Authors:  Matthew J Feinstein; Milana Bogorodskaya; Gerald S Bloomfield; Rajesh Vedanthan; Mark J Siedner; Gene F Kwan; Christopher T Longenecker
Journal:  Curr Cardiol Rep       Date:  2016-11       Impact factor: 2.931

5.  HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans.

Authors:  Jonathan Buggey; Leo Yun; Chung-Lieh Hung; Cissy Kityo; Grace Mirembe; Geoffrey Erem; Tiffany Truong; Isaac Ssinabulya; W H Wilson Tang; Brian D Hoit; Grace A McComsey; Chris T Longenecker
Journal:  Heart       Date:  2019-09-19       Impact factor: 5.994

6.  Clinical characteristics of HIV-infected patients with adjudicated heart failure.

Authors:  Alexandra B Steverson; Anna E Pawlowski; Daniel Schneider; Prasanth Nannapaneni; Jes M Sanders; Chad J Achenbach; Sanjiv J Shah; Donald M Lloyd-Jones; Matthew J Feinstein
Journal:  Eur J Prev Cardiol       Date:  2017-09-25       Impact factor: 7.804

Review 7.  Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations.

Authors:  Mabel Toribio; Tomas G Neilan; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.071

Review 8.  Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research.

Authors:  Joshua Remick; Vasiliki Georgiopoulou; Catherine Marti; Igho Ofotokun; Andreas Kalogeropoulos; William Lewis; Javed Butler
Journal:  Circulation       Date:  2014-04-29       Impact factor: 29.690

9.  Inflammation and Fibrosis in HIV: Getting to the Heart of the Matter.

Authors:  Priscilla Y Hsue; Ahmed Tawakol
Journal:  Circ Cardiovasc Imaging       Date:  2016-03       Impact factor: 7.792

Review 10.  Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries.

Authors:  Gerald S Bloomfield; Fawaz Alenezi; Felix A Barasa; Rebecca Lumsden; Bongani M Mayosi; Eric J Velazquez
Journal:  JACC Heart Fail       Date:  2015-08       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.